In a meta-analysis of five clinical trials where abacavir was added to intensify therapy, of 166 subjects, 123 (74%) had M184V/ I, 50 (30%) had T215Y/ F, 45 (27%) had M41L, 30 (18%) had K70R and 25 (15%) had D67N.
Viie kliinilise uuringu (kus abakaviir lisati ravitoime tugevdamiseks) metaanalüüsi põhjal esines 166 patsiendist 123- l (74%) M184V/ I, 50- l (30%) T215Y/ F, 45- l (27%) M41L, 30- l (18%) K70R ja 25 (15%) D67N.